Biogen’s shares surge again as FDA hurries Alzheimer’s drug reviewBiogen’s Alzheimer’s drug aducanumab could be on the market in the next few months after the FDA accepted Share XBiogen’s shares surge again as FDA hurries Alzheimer’s drug reviewhttps://pharmaphorum.com/news/biogens-shares-surge-again-as-fda-hurries-alzheimers-drug-review/
Biogen and Eisai trial drug in asymptomatic Alzheimer’s diseaseBiogen and Eisai have begun a new phase 3 study testing an Alzheimer’s antibody drug aimed at patients without symptoms but Share XBiogen and Eisai trial drug in asymptomatic Alzheimer’s diseasehttps://pharmaphorum.com/news/biogen-and-eisai-trial-drug-in-asymptomatic-alzheimers-disease/
Biogen shares pop as it completes filing for Alzheimer’s drug aducanumabBiogen’s share price was up sharply on Wednesday after the big pharma completed its filing of its Alzheimer’s Share XBiogen shares pop as it completes filing for Alzheimer’s drug aducanumabhttps://pharmaphorum.com/news/biogen-shares-pop-as-it-completes-filing-for-alzheimers-drug-aducanumab/
FDA clears US trials of Green Valley’s Alzheimer’s drugChina’s Shanghai Green Valley Pharmaceuticals has clearance to begin a late stage clinical trial to support a US filing Share XFDA clears US trials of Green Valley’s Alzheimer’s drughttps://pharmaphorum.com/news/fda-clears-us-trials-of-green-valleys-of-alzheimers-drug/
Warren Buffet shocks Wall Street with Biogen gambleBiogen is trying to resurrect two failed trials of its Alzheimer’s drug aducanumab – and superstar investor Warren Share XWarren Buffet shocks Wall Street with Biogen gamblehttps://pharmaphorum.com/news/warren-buffet-shocks-wall-street-with-biogen-gamble/
Is Tecfidera’s patent win a pyrrhic victory for Biogen?Shares in Biogen jumped last week after the company successfully defended its blockbuster MS drug Tecfidera from a Share XIs Tecfidera’s patent win a pyrrhic victory for Biogen?https://pharmaphorum.com/views-analysis-sales-marketing/tecfideras-patent-pyrrhic-victory-biogen/
